Actually the advantage of Ibsrela is, that it's not a secretagogue but has a very different mode of action. The company is not competing with the secretagogues but target the patients who are not well managed by Trulance or Linzess or other drugs.After two+ years of being FDA approved. They are finally bringing it to market. I believe the reason why it took this long is because they wanted to market tenapanor to treat another disease that would have been more profitable. I'm not sure why they shifted gears, perhaps the other market didn't work out for them.
From what I've read, it's basically another secretatatogue like Linzess or Trulance. My hope is that it will be less severe and cause less D while still being an effective treatment for the C.
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialty biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...www.prnewswire.com